ConductScience.org, home

Paper · 21689613

Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma.

Siddique A and 1 other. Clin Liver Dis, 2011. Cited by 54 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Papers, record 21689613. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21689613

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma.
PubMed
Journal
Clin Liver Dis
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
54
iCite
Relative citation ratio, by iCite
1.34
iCite
Revised in PubMed
2024-03-23
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Siddique AAsma
2Kowdley KVKris V

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Insulin ResistanceMajor topic
Liver NeoplasmsMajor topic
Animals
Humans
Liver Neoplasms, Experimental

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
K24 DK002957NIDDK NIH HHSUnited StatesK24DK002957PubMed and NIH
K24 DK02957NIDDK NIH HHSUnited StatesK24DK002957PubMed and NIH

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References103

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18,571,133IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.Science1996https://conductscience.org/library/papers/8571133PubMed
212,883,486Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.Hepatology2003https://conductscience.org/library/papers/12883486PubMed
315,313,394
An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.
Biochem Pharmacol2004https://conductscience.org/library/papers/15313394PubMed
417,301,264Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study.Cancer Epidemiol Biomarkers Prev2007https://conductscience.org/library/papers/17301264PubMed
520,078,219Nonalcoholic fatty liver disease: pathology and pathogenesis.Annu Rev Pathol2010https://conductscience.org/library/papers/20078219PubMed
614,762,783Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.Gastroenterology2004https://conductscience.org/library/papers/14762783PubMed
711,686,294PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?J Cell Sci2001https://conductscience.org/library/papers/11686294PubMed
810,854,232Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition.Am J Pathol2000https://conductscience.org/library/papers/10854232PubMed
919,557,293Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations.Rev Diabet Stud2009https://conductscience.org/library/papers/19557293PubMed
109,039,259p53, the cellular gatekeeper for growth and division.Cell1997https://conductscience.org/library/papers/9039259PubMed

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.

PMIDTitleJournalYearIn PapersSource
42,412,361New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study.Hepatol Int2026https://conductscience.org/library/papers/42412361PubMed
42,317,961Adiponectin's Role in the Development and Progression of Differentiated Thyroid Carcinoma: A Narrative Review of Current Evidence.Cureus2026https://conductscience.org/library/papers/42317961PubMed
42,101,220Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post-DAA Management.J Med Virol2026https://conductscience.org/library/papers/42101220PubMed
41,667,791Insulin resistance: mechanisms and therapeutic interventions.Mol Biomed2026https://conductscience.org/library/papers/41667791PubMed
40,265,012Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.Front Oncol2025https://conductscience.org/library/papers/40265012PubMed
39,006,727A Retrospective Cohort Study From the National Inpatient Sample Database (2016-2019): Does Obesity Affect the Outcomes of Hospitalization Due to Hepatocellular Carcinoma?Cureus2024https://conductscience.org/library/papers/39006727PubMed
38,586,586MHIF-MSEA: a novel model of miRNA set enrichment analysis based on multi-source heterogeneous information fusion.Front Genet2024https://conductscience.org/library/papers/38586586PubMed
38,398,797Current Trends on the Involvement of Zinc, Copper, and Selenium in the Process of Hepatocarcinogenesis.Nutrients2024https://conductscience.org/library/papers/38398797PubMed
37,545,641Serum resistin and the risk for hepatocellular carcinoma in diabetic patients.World J Gastroenterol2023https://conductscience.org/library/papers/37545641PubMed
37,361,533Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37361533PubMed

1 to 10 of 31

See all 31 cited by

Genes55

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21689613

GET https://conductscience.org/api/papers/v1/21689613/references?page=2